Heather Landau

7.9k total citations
200 papers, 2.6k citations indexed

About

Heather Landau is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Heather Landau has authored 200 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Hematology, 127 papers in Molecular Biology and 49 papers in Oncology. Recurrent topics in Heather Landau's work include Multiple Myeloma Research and Treatments (117 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (88 papers) and Protein Degradation and Inhibitors (27 papers). Heather Landau is often cited by papers focused on Multiple Myeloma Research and Treatments (117 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (88 papers) and Protein Degradation and Inhibitors (27 papers). Heather Landau collaborates with scholars based in United States, Italy and Germany. Heather Landau's co-authors include Raymond L. Comenzo, Hani Hassoun, Sergio Giralt, Giampaolo Merlini, Vaishali Sanchorawala, Michael Rosenzweig, Spencer Guthrie, Morie A. Gertz, David J. Chung and Sean M. Devlin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

Heather Landau

178 papers receiving 2.5k citations

Peers

Heather Landau
Taxiarchis Kourelis United States
MA Gertz United States
Kristina Carlson Sweden
N. L. Fox United States
Nikolaos Kanellias Greece
Dimitrios Christoulas Greece
Dil Sahali France
Jan Samuelsson Sweden
Xenophon Yataganas Greece
Katy Rezvani United States
Taxiarchis Kourelis United States
Heather Landau
Citations per year, relative to Heather Landau Heather Landau (= 1×) peers Taxiarchis Kourelis

Countries citing papers authored by Heather Landau

Since Specialization
Citations

This map shows the geographic impact of Heather Landau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather Landau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather Landau more than expected).

Fields of papers citing papers by Heather Landau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather Landau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather Landau. The network helps show where Heather Landau may publish in the future.

Co-authorship network of co-authors of Heather Landau

This figure shows the co-authorship network connecting the top 25 collaborators of Heather Landau. A scholar is included among the top collaborators of Heather Landau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heather Landau. Heather Landau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Comenzo, Raymond L., et al.. (2024). A Pilot Study Assessing the Accuracy of AI ChatGPT Responses for AL Amyloidosis. European Journal Of Haematology. 114(3). 495–499.
2.
Derkach, Andriy, Billel Gasmi, Theodora Anagnostou, et al.. (2023). T-Cell Exhaustion Signature Predicts Early Relapse after Autologous Stem Cell Transplant for Multiple Myeloma: BMT CTN 0702 Secondary Immune Analysis. Blood. 142(Supplement 1). 3326–3326. 1 indexed citations
3.
Gertz, Morie A., Rafat Abonour, Sarah N. Gibbs, et al.. (2023). Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis. ClinicoEconomics and Outcomes Research. Volume 15. 673–680.
4.
Firestone, Ross, Andriy Derkach, Kylee Maclachlan, et al.. (2023). P-486 Clinical significance of baseline body mass index and its trajectory during triplet induction therapy in newly diagnosed multiple myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S307–S308. 1 indexed citations
5.
Scordo, Michael, Leah Gilbert, Jessica Flynn, et al.. (2022). Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation. Blood Advances. 7(8). 1536–1544. 4 indexed citations
6.
Landau, Heather, Elizabeth Rodríguez, Allison J. Applebaum, et al.. (2022). Pilot Trial of Homebound Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 28(12). 832.e1–832.e7. 5 indexed citations
7.
Hultcrantz, Malin, Even H. Rustad, Venkata Yellapantula, et al.. (2022). Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. Clinical Cancer Research. 28(10). 2160–2166. 1 indexed citations
8.
Lentzsch, Suzanne, Raymond L. Comenzo, Jeffrey A. Zonder, et al.. (2020). Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. Journal of Clinical Oncology. 38(13). 1455–1462. 35 indexed citations
9.
Yellapantula, Venkata D., Malin Hultcrantz, Even H. Rustad, et al.. (2020). Correction: Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal. 10(1). 1 indexed citations
10.
Yellapantula, Venkata D., Malin Hultcrantz, Even H. Rustad, et al.. (2019). Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. Blood Cancer Journal. 9(12). 101–101. 35 indexed citations
11.
Dispenzieri, Angela, Ashutosh Wechalekar, Stefan Schönland, et al.. (2019). Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL). Blood. 134(Supplement_1). 139–139. 32 indexed citations
12.
Pianko, Matthew J., Jessica Flynn, Sean M. Devlin, et al.. (2018). Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. Blood. 132(Supplement 1). 5591–5591.
13.
14.
Landau, Heather, Elyn Riedel, Anthony F. Yu, et al.. (2017). Prognostic and Added Value of Two-Dimensional Global Longitudinal Strain for Prediction of Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Hematopoietic Cell Transplantation. Journal of the American Society of Echocardiography. 31(1). 64–70. 39 indexed citations
15.
Gertz, Morie A., Heather Landau, Raymond L. Comenzo, et al.. (2016). First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. Journal of Clinical Oncology. 34(10). 1097–1103. 147 indexed citations
16.
Devlin, Sean M., Jill Vanak, Heather Landau, et al.. (2016). Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for stem cell mobilization in multiple myeloma: efficacy and cost analysis study. Bone Marrow Transplantation. 51(4). 546–552. 38 indexed citations
17.
Lendvai, Nikoletta, Patrick Hilden, Sean M. Devlin, et al.. (2014). A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood. 124(6). 899–906. 65 indexed citations
18.
Landau, Heather, Samuel McNeely, Jayasree S. Nair, et al.. (2012). The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53 -Mutated Multiple Myeloma Cells. Molecular Cancer Therapeutics. 11(8). 1781–1788. 48 indexed citations
19.
Zhou, Ping, James E. Hoffman, Heather Landau, et al.. (2011). Clonal Plasma Cell Pathophysiology and Clinical Features of Disease Are Linked to Clonal Plasma Cell Expression of Cyclin D1 in Systemic Light-Chain Amyloidosis. Clinical Lymphoma Myeloma & Leukemia. 12(1). 49–58. 24 indexed citations
20.
Landau, Heather, et al.. (1972). An uncommon cause of high serum protein-bound iodine.. PubMed. 8(10). 1749–51. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taxiarchis Kourelis Breakdown of academic impact, for papers by MA Gertz Breakdown of academic impact, for papers by Kristina Carlson Breakdown of academic impact, for papers by N. L. Fox Breakdown of academic impact, for papers by Nikolaos Kanellias Breakdown of academic impact, for papers by Dimitrios Christoulas Breakdown of academic impact, for papers by Dil Sahali Breakdown of academic impact, for papers by Jan Samuelsson Breakdown of academic impact, for papers by Xenophon Yataganas Breakdown of academic impact, for papers by Katy Rezvani
Rankless by CCL
2026